Quick Answer
Protara Therapeutics, Inc. reported Operating Income of -$64.55 million for fiscal year 2025.
Protara Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$64.55M | -31.3% |
| 2024 | -$49.15M | -12.7% |
| 2023 | -$43.61M | +35.0% |
| 2022 | -$67.06M | -41.2% |
| 2021 | -$47.49M | -37.9% |
| 2020 | -$34.44M | -339.9% |
| 2019 | -$7.83M | +63.4% |
| 2018 | -$21.37M | +29.6% |
| 2017 | -$30.36M | -5.8% |
| 2016 | -$28.70M | -37.5% |
| 2015 | -$20.87M | -175.3% |
| 2014 | -$7.58M | -6.4% |
| 2013 | -$7.12M | +10.9% |
| 2012 | -$8.00M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$14.76M | -19.7% | +11.0% |
| June 30, 2025 | -$16.59M | -55.6% | -17.4% |
| March 31, 2025 | -$14.12M | -19.2% | -14.5% |
| September 30, 2024 | -$12.33M | -15.2% | -15.7% |
| June 30, 2024 | -$10.66M | +12.2% | +10.0% |
| March 31, 2024 | -$11.85M | -21.8% | -10.8% |
| September 30, 2023 | -$10.70M | -34.2% | +11.9% |
| June 30, 2023 | -$12.14M | -39.5% | -24.7% |
- Protara Therapeutics, Inc. showed a decrease of -31.3% in Operating Income compared to the prior fiscal year.
- Over the 2012–2025 period, Protara Therapeutics, Inc.’s operating income has declined by 707.3% (from -$8.00 million to -$64.55 million).
- The most recent figure is from Protara Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: